Drug General Information (ID: DDIPSRC5KX)
Drug Name			Heparin		Drug Info		Antithrombin Alfa		Drug Info
Drug Type		Small molecule				Protein/peptide
Therapeutic Class		Anticoagulants				Recombinant Antithrombin

Mechanism of Heparin-Antithrombin Alfa Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Heparin				Antithrombin Alfa
Mechanism		Risk of bleeding Anticoagulant				Risk of bleeding Anticoagulant
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Heparin and Antithrombin Alfa

Recommended Action
Management		If concomitant therapy is necessary, heparin dose reductions may be necessary to avoid bleeding. Close clinical and laboratory monitoring is recommended during concurrent use.

References
1	Product Information. ATryn (antithrombin recombinant). Ovation Pharmaceuticals Inc, Deerfield, IL.